Solid Biosciences Inc (SLDB)

$5.48 -0.42 (-7.12%)
Market Cap 459.43M
Revenue (ttm) 0.00
Net Income (ttm) -124.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 782,700
Avg Vol 1,096,226
Day's Range N/A - N/A
Shares Out 77.87M
Stochastic %K 61%
Beta 2.53
Analysts Strong Sell
Price Target $15.58

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopath...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 337 4680
Address:
500 Rutherford Avenue, Third Floor, Charlestown, United States
Stockboi_
Stockboi_ Oct. 2 at 9:37 PM
$SLDB flag broken for me. Stopping out here. Have fun yall
0 · Reply
diggs24
diggs24 Oct. 1 at 8:03 PM
$SLDB Almost like clockwork there's a big push upwards towards the closing bell. It's as if someone(s) are trying to ensure they are holding a heavy position in this overnight. Anyone else seeing this?
1 · Reply
Stockboi_
Stockboi_ Oct. 1 at 5:50 PM
$SLDB as long as the flag don’t break we litttt
0 · Reply
pharmd2828
pharmd2828 Oct. 1 at 2:02 PM
$SLDB https://finance.yahoo.com/news/solid-biosciences-present-upcoming-scientific-120000645.html
0 · Reply
Winning_calls
Winning_calls Sep. 29 at 2:13 PM
$SLDB 😘
0 · Reply
jposmak
jposmak Sep. 29 at 12:21 PM
$SLDB first rule of investment do not believe on internet
0 · Reply
Winning_calls
Winning_calls Sep. 29 at 3:00 AM
$SLDB pick me up @ $6.15
0 · Reply
pharmd2828
pharmd2828 Sep. 28 at 8:05 PM
$SLDB where does SLDB go from here and after great presentation on Friday in Italy ?? Your thoughts? I am long SLDB !!
0 · Reply
pharmd2828
pharmd2828 Sep. 27 at 10:34 PM
$SLDB https://share.google/PdAM61CYOp3vOrXGB
0 · Reply
Doozio
Doozio Sep. 27 at 3:59 PM
$SLDB chop chop huckleberries…. It was always 🐒🍌🧠⏰♾️
0 · Reply
Latest News on SLDB
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2025, 4:05 PM EDT - 5 days ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Present at Upcoming Scientific Meetings

Oct 1, 2025, 8:00 AM EDT - 5 days ago

Solid Biosciences to Present at Upcoming Scientific Meetings

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Sep 25, 2025, 8:00 AM EDT - 11 days ago

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Sep 23, 2025, 8:00 AM EDT - 13 days ago

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Sep 23, 2025, 8:00 AM EDT - 13 days ago

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 4:28 PM EDT - 4 weeks ago

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript

Solid Biosciences to Participate at Upcoming Investor Conferences

Aug 28, 2025, 8:00 AM EDT - 5 weeks ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 4:07 PM EDT - 7 weeks ago

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 23, 2025, 8:00 AM EDT - 2 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

Jul 11, 2025, 3:02 PM EDT - 3 months ago

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Jul 10, 2025, 8:00 AM EDT - 3 months ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 8, 2025, 4:05 PM EDT - 3 months ago

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 4 months ago

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025, 4:06 PM EDT - 5 months ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 5 months ago

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Apr 29, 2025, 8:00 AM EDT - 5 months ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Apr 8, 2025, 4:50 PM EDT - 6 months ago

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 6 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SRPT TSHA XBI

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 12, 2025, 8:00 AM EDT - 7 months ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 6, 2025, 4:16 PM EST - 7 months ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Feb 18, 2025, 12:29 PM EST - 8 months ago

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 7:00 AM EST - 8 months ago

Solid Biosciences Announces Pricing of Underwritten Offering

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Feb 18, 2025, 6:45 AM EST - 8 months ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Jan 21, 2025, 6:27 PM EST - 9 months ago

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Jan 21, 2025, 8:30 AM EST - 9 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 15, 2025, 4:05 PM EST - 9 months ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 9 months ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Jan 7, 2025, 4:15 PM EST - 9 months ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 23, 2024, 4:05 PM EST - 10 months ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Dec 13, 2024, 1:52 PM EST - 10 months ago

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 11 months ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 11 months ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:08 PM EDT - 1 year ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2024, 4:19 PM EDT - 1 year ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

May 15, 2024, 7:52 AM EDT - 1 year ago

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 10, 2024, 7:32 PM EDT - 1 year ago

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Apr 1, 2024, 7:45 AM EDT - 1 year ago

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Mar 13, 2024, 7:44 AM EDT - 1 year ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 16, 2024, 11:01 PM EST - 1 year ago

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Jan 16, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Announces $109 Million Private Placement

Jan 8, 2024, 7:09 AM EST - 1 year ago

Solid Biosciences Announces $109 Million Private Placement

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Nov 8, 2023, 4:17 PM EST - 2 years ago

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Aug 14, 2023, 4:17 PM EDT - 2 years ago

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Solid Biosciences to Participate at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the Jefferies Healthcare Conference

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

May 22, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

May 16, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

Solid Biosciences Provides First Quarter Business Update and Financial Results

May 11, 2023, 7:30 AM EDT - 2 years ago

Solid Biosciences Provides First Quarter Business Update and Financial Results

Stockboi_
Stockboi_ Oct. 2 at 9:37 PM
$SLDB flag broken for me. Stopping out here. Have fun yall
0 · Reply
diggs24
diggs24 Oct. 1 at 8:03 PM
$SLDB Almost like clockwork there's a big push upwards towards the closing bell. It's as if someone(s) are trying to ensure they are holding a heavy position in this overnight. Anyone else seeing this?
1 · Reply
Stockboi_
Stockboi_ Oct. 1 at 5:50 PM
$SLDB as long as the flag don’t break we litttt
0 · Reply
pharmd2828
pharmd2828 Oct. 1 at 2:02 PM
$SLDB https://finance.yahoo.com/news/solid-biosciences-present-upcoming-scientific-120000645.html
0 · Reply
Winning_calls
Winning_calls Sep. 29 at 2:13 PM
$SLDB 😘
0 · Reply
jposmak
jposmak Sep. 29 at 12:21 PM
$SLDB first rule of investment do not believe on internet
0 · Reply
Winning_calls
Winning_calls Sep. 29 at 3:00 AM
$SLDB pick me up @ $6.15
0 · Reply
pharmd2828
pharmd2828 Sep. 28 at 8:05 PM
$SLDB where does SLDB go from here and after great presentation on Friday in Italy ?? Your thoughts? I am long SLDB !!
0 · Reply
pharmd2828
pharmd2828 Sep. 27 at 10:34 PM
$SLDB https://share.google/PdAM61CYOp3vOrXGB
0 · Reply
Doozio
Doozio Sep. 27 at 3:59 PM
$SLDB chop chop huckleberries…. It was always 🐒🍌🧠⏰♾️
0 · Reply
Impatient_Investor
Impatient_Investor Sep. 25 at 4:53 PM
$SLDB pump and dump garbage
1 · Reply
pharmd2828
pharmd2828 Sep. 25 at 1:08 PM
$SLDB https://finance.yahoo.com/news/solid-biosciences-present-2025-neuromuscular-120000137.html
0 · Reply
StockScanners
StockScanners Sep. 25 at 1:18 AM
$SLDB keep watch if this hold above 5.80
0 · Reply
Bio_Invest101
Bio_Invest101 Sep. 24 at 8:29 PM
$SLDB 2.65 Million shares more than doubled traded for yesterday’s news. Lol. We seem always slow reaction on company development news and had the Company disclosed some details of licensing deal it might have boosted it up higher to $7 So question is why no details ?
0 · Reply
Johnny_443
Johnny_443 Sep. 24 at 5:37 PM
$SLDB any hint on why + 14% today?
3 · Reply
pharmd2828
pharmd2828 Sep. 23 at 1:27 PM
$SLDB https://finance.yahoo.com/news/solid-biosciences-announces-licensing-agreement-120000219.html
0 · Reply
pharmd2828
pharmd2828 Sep. 23 at 12:43 PM
$SLDB https://finance.yahoo.com/news/solid-biosciences-announces-licensing-agreement-120000219.html
0 · Reply
Stonkleader55
Stonkleader55 Sep. 22 at 5:58 PM
$SLDB when is this going to explode to $20 ?
1 · Reply
Bio_Invest101
Bio_Invest101 Sep. 12 at 9:22 PM
$SLDB $SRPT Seems Adcom won’t be needed any more from outside experts… https://www.fiercepharma.com/pharma/under-trump-fda-seeks-abandon-expert-reviews-new-drugs
1 · Reply
Bio_Invest101
Bio_Invest101 Sep. 11 at 11:10 AM
$SLDB SI are still close to record high.
0 · Reply
flexdiggs
flexdiggs Sep. 10 at 6:22 PM
$SLDB they really tried to shake the tree here, company is on track with their trials and money. Steady as she goes, we'll see a breakout soon, gl.
1 · Reply
Impatient_Investor
Impatient_Investor Sep. 10 at 7:23 AM
$SLDB pump and dump garbage
1 · Reply